In contrast, anti-γc antibody could suppress both IL-2 triggered cytotoxicity against tumor cells (Figures 5(a) and 5(b)) and soluble factor release (Figure 5(d)–5(i)) when compared to anti-CD25 treated groups. The gene discussed is IL2; the disease is neoplasm.